« Back
Home /
ACPP Peptide - middle region (AAP41913)

ACPP Peptide - middle region (AAP41913)

Item no.	AAP41913
Manufacturer	AVIVA Systems Biology
Amount	100 ug
Category	Oncology Metabolism Diabetes Peptides & Proteins Western Blot Peptides By Organ Testicular & Prostate Cancer
Type	Peptides
Format	Lyophilized powder
Applications	WB
Specific against	other
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	ACP-3, ACP3, PAP
Similar products	ACPP
Available
Description	This is a synthetic peptide designed for use in combination with anti-ACPP antibody (Catalog #: ARP41913_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Gene symbol	ACPP
Protein size	386
Molecular weight	41kDa
Product format	Lyophilized powder
Gene id	55
Reconstitution and storage	Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20C. Avoid repeat freeze-thaw cycles.
Partner proteins	ACPP, ERBB2, SHBG, ACPP
Description of target	This gene encodes an enzyme that catalyzes the conversion of orthophosphoric monoester to alcohol and orthophosphate. It is synthesized under androgen regulation and is secreted by the epithelial cells of the prostate gland. An alternatively spliced trans

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 ug

available

Delivery expected until 8/30/2024